ALX Oncology Holdings Inc. (NasdaqGS: ALXO)
Health Care · Biotechnology · US
$1.99
-2.45% today · +85.5% 1Y
ALX Oncology Holdings Inc. (NasdaqGS: ALXO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $282.09M and employs 48 people.
Over the last twelve months the share price has gained 85.5%, trading between 0.96 and 2.66.
Tweenvest scores ALX Oncology Holdings Inc. across four factors: quality 26/100. Its strongest factor is quality.
ALXO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $282.09M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.93
- Dividend yield
- —
- Beta (5Y)
- 0.40
- 52-week high
- $2.66
- 52-week low
- $0.96
- Avg volume (3M)
- —
- Shares outstanding
- 138.28M
- Employees
- 48
- Next earnings
- —
About ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
- ISIN
- US00166B1052
- Founded
- 2015
- Listed since
- Jul 17, 2020
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $265.43 | +0.18% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.98 | +0.38% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.44 | +0.22% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.78 | +0.13% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $825.89 | -0.98% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $139.44 | -3.88% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.